Atazanavir/Ritonavir Maintenance Therapy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00084019
Recruitment Status : Completed
First Posted : June 7, 2004
Last Update Posted : June 3, 2014
Information provided by (Responsible Party):
National Institute of Allergy and Infectious Diseases (NIAID)

June 4, 2004
June 7, 2004
June 3, 2014
July 2004
Not Provided
Virologic failure, defined as 2 consecutive viral load measurements of 200 copies/ml or greater, at or before Week 30 (24 weeks on ATV/RTV alone)
Same as current
Complete list of historical versions of study NCT00084019 on Archive Site
  • Grade 3 and 4 laboratory abnormalities and signs and symptoms
  • time to treatment discontinuation because of toxicity or intolerance
  • virologic failure at or before Week 54
  • viral load determined by modified ultrasensitive RT-PCR assay
  • minor PI variants at virologic failure
  • total cholesterol, high-density lipoprotein (HDL) cholesterol, calculated low-density lipoprotein (LDL) cholesterol, and triglycerides
  • CD4 cell count and percentages at Weeks 30 and 54
  • self-reported adherence scores
  • plasma drug levels characterized by Cmin and AUC
  • detectable viral load in the genital compartment at Week 30
Not Provided
Not Provided
Not Provided
Atazanavir/Ritonavir Maintenance Therapy
A Prospective, Open-Label, Pilot Trial of Regimen Simplification to Atazanavir/Ritonavir Alone as Maintenance Antiretroviral Therapy After Sustained Virologic Suppression

Long-term side effects, the expense of medications, and the difficulty of taking medications continuously for long periods of time are all problems with complicated anti-HIV drug regimens. The purpose of this study is to determine whether two drugs, atazanavir (ATV) and ritonavir (RTV), will control HIV infection when taken together without any other anti-HIV drugs after 48 weeks of viral suppression.

Hypothesis: Simplified maintenance therapy with ATV and RTV alone after virologic suppression does not markedly increase the risk of virologic failure.

The expense, difficulty, and long-term adverse events associated with sustained adherence to combination antiretroviral therapy emphasize the need for simpler, alternative treatment strategies for HIV infection. Studies have shown that single protease inhibitor (PI) maintenance therapy may provide sufficient virologic suppression while reducing the risk of nucleoside reverse transcriptase inhibitor (NRTI)-associated metabolic complications. However, it is not known whether ritonavir-boosted atazanavir (ATV/RTV) maintenance therapy would be effective in controlling HIV replication in the genital compartments and whether viral load testing by blood collection would be effective in detecting elevated levels of HIV in the genital compartments. This study will determine whether simplified maintenance therapy with ATV/RTV after 48-week virologic suppression will increase the likelihood of virologic failure.

This study will last 54 weeks. Participants will undergo an electrocardiogram (EKG) at screening. At study start, participants will switch from their current PIs to ATV/RTV and stay on their current NRTIs until Week 6, when they will discontinue their NRTIs and remain on a maintenance regimen of ATV/RTV alone for the duration of the study. Study visits will take place at Weeks 3 and 6, then every 4 weeks until Week 30, then every 8 weeks until the end of the study at Week 54. Medication assessment, physical exam, and blood work will occur at each study visit. At Week 30, viral load will be measured in the genital secretions of both male and female study participants.

Not Applicable
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
HIV Infections
  • Drug: Atazanavir
  • Drug: Ritonavir
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
May 2006
Not Provided

Inclusion Criteria:

  • HIV infected
  • On first antiretroviral regimen, including at least 2 NRTIs and 1 PI, for at least 48 weeks immediately prior to study entry
  • CD4 count of 250 cells/mm3 or greater
  • Viral load less than 50 copies/ml within 30 days prior to entry
  • Willing to use acceptable methods of contraception

Exclusion Criteria:

  • Current or prior use of an NNRTI
  • Certain PI mutations
  • Hepatitis B infection within 90 days prior to study entry
  • Certain therapies or medications within 30 days prior to study entry
  • Heartbeat abnormalities or symptoms potentially related to heart block, such as unexplained fainting, dizziness, or palpitations, occurring within 180 days prior to study entry
  • Drug or alcohol use or dependence that would interfere with adherence to the study requirements
  • Serious illness requiring systemic treatment or hospitalization until the participant either completes therapy or has been clinically stable on therapy for at least 14 days prior to study entry
  • Allergy or sensitivity to study medications or their formulations
  • Current involuntarily incarceration for treatment of either a mental or physical illness
  • Treatment for an active AIDS-defining opportunistic infection within 30 days prior to screening
  • Pregnant or breastfeeding
Sexes Eligible for Study: All
18 Years and older   (Adult, Older Adult)
Contact information is only displayed when the study is recruiting subjects
Puerto Rico,   United States
10096 ( Registry Identifier: DAIDS ES )
ACTG A5201
Not Provided
Not Provided
Not Provided
National Institute of Allergy and Infectious Diseases (NIAID)
National Institute of Allergy and Infectious Diseases (NIAID)
Not Provided
Study Chair: Susan Swindells, MD University of Nebraska
National Institute of Allergy and Infectious Diseases (NIAID)
June 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP